Skip to main content

Recarbrio Side Effects

Generic name: cilastatin / imipenem / relebactam

Medically reviewed by Last updated on Aug 30, 2023.

Note: This document contains side effect information about cilastatin / imipenem / relebactam. Some dosage forms listed on this page may not apply to the brand name Recarbrio.

Applies to cilastatin / imipenem / relebactam: intravenous powder for solution.

Serious side effects of Recarbrio

Along with its needed effects, cilastatin/imipenem/relebactam may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking cilastatin / imipenem / relebactam:

More common

Less common

Incidence not known

Other side effects of Recarbrio

Some side effects of cilastatin / imipenem / relebactam may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to cilastatin / imipenem / relebactam: intravenous powder for injection.


Very common (10% or more): Increased AST (up to 11.7%)

Common (1% to 10%): Increased ALT


-Common (1% to 10%): Increased ALT, increased AST

-Uncommon (0.1% to 1%): Increased serum bilirubin

-Rare (0.01% to 0.1%): Hepatic failure, hepatitis

-Very rare (less than 0.01%): Fulminant hepatitis

-Frequency not reported: Jaundice[Ref]


Very common (10% or more): Anemia (included anemia, decreased hemoglobin; up to 10.5%)

Frequency not reported: Thrombocytopenia


-Common (1% to 10%): Anemia, eosinophilia

-Uncommon (0.1% to 1%): Pancytopenia, neutropenia, leukopenia, thrombocytopenia, thrombocytosis, positive Coombs test, prolonged prothrombin time, decreased hemoglobin

-Rare (0.01% to 0.1%): Agranulocytosis

-Very rare (less than 0.01%): Hemolytic anemia, bone marrow depression

-Frequency not reported: Increased eosinophils, increased eosinophil count[Ref]


Common (1% to 10%): Hypokalemia (included hypokalemia, decreased blood potassium), hyponatremia (included hyponatremia, decreased blood sodium)


Common (1% to 10%): Diarrhea, nausea, vomiting, increased lipase, constipation

Frequency not reported: Clostridioides difficile-associated diarrhea


-Common (1% to 10%): Nausea, diarrhea, vomiting, increased lipase

-Rare (0.01% to 0.1%): Pseudomembranous colitis, staining of teeth and/or tongue

-Very rare (less than 0.01%): Gastroenteritis, hemorrhagic colitis, abdominal pain, heartburn, glossitis, tongue papilla hypertrophy, increased salivation[Ref]


Common (1% to 10%): Rash (included rash, erythematous rash, generalized rash)


-Common (1% to 10%): Rash (e.g., exanthematous)

-Uncommon (0.1% to 1%): Urticaria, pruritus

-Rare (0.01% to 0.1%): Toxic epidermal necrolysis, angioedema, Stevens-Johnson syndrome, erythema multiforme, exfoliative dermatitis

-Very rare (less than 0.01%): Hyperhidrosis, skin texture changes[Ref]


Common (1% to 10%): Pyrexia


-Common (1% to 10%): Pyrexia, increased serum alkaline phosphatase

-Rare (0.01% to 0.1%): Candidiasis

-Very rare (less than 0.01%): Chest discomfort, asthenia/weakness

-Frequency not reported: Increased blood lactate dehydrogenase[Ref]

Nervous system

Common (1% to 10%): Headache

Uncommon (0.1% to 1%): Central nervous system (CNS) adverse reactions (included agitation, apathy, confusional states, delirium, disorientation, slow speech, somnolence)


-Common (1% to 10%): Headache, CNS adverse reactions

-Uncommon (0.1% to 1%): Seizures, myoclonic activity, dizziness, somnolence

-Rare (0.01% to 0.1%): Encephalopathy, paresthesia, focal tremor, taste perversion, hearing loss

-Very rare (less than 0.01%): Aggravation of myasthenia gravis, vertigo, tinnitus

-Frequency not reported: Dyskinesia[Ref]


Common (1% to 10%): Phlebitis/infusion site reactions (included infusion site phlebitis, infusion site erythema, infusion site pain)


-Common (1% to 10%): Phlebitis/infusion site reactions

-Uncommon (0.1% to 1%): Local pain and induration at injection site[Ref]


Common (1% to 10%): Hypertension (included hypertension, increased blood pressure)


-Common (1% to 10%): Hypertension, thrombophlebitis

-Uncommon (0.1% to 1%): Hypotension

-Very rare (less than 0.01%): Cyanosis, tachycardia, palpitations, flushing[Ref]


Uncommon (0.1% to 1%): Increased blood creatinine, decreased creatinine renal clearance


-Common (1% to 10%): Increased blood creatinine

-Uncommon (0.1% to 1%): Increased blood urea nitrogen

-Rare (0.01% to 0.1%): Acute renal failure[Ref]



-Uncommon (0.1% to 1%): Hallucinations, confusional states

-Frequency not reported: Agitation[Ref]



-Rare (0.01% to 0.1%): Anaphylactic reactions


-Frequency not reported: Hypersensitivity (anaphylactic) reactions[Ref]



-Rare (0.01% to 0.1%): Oliguria/anuria, polyuria, urine discoloration

-Very rare (less than 0.01%): Pruritus vulvae[Ref]

Urine discoloration was harmless (not to be confused with hematuria).[Ref]



-Very rare (less than 0.01%): Dyspnea, hyperventilation, pharyngeal pain[Ref]



-Very rare (less than 0.01%): Polyarthralgia, thoracic spine pain[Ref]


1. Cerner Multum, Inc. "UK Summary of Product Characteristics."

2. (2019) "Product Information. Recarbrio (imipenem/cilastatin/relebactam)." Merck & Co., Inc

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.